

Consolidated Financial Result Digest FY2027/3 1Q

(Fiscal Year Ended March 31, 2027)

Taiyo Holdings Co., Ltd.
(4626: Prime Market of Tokyo Stock Exchange)
July 31, 2026



Any information incorporated in this document is not intended for the purposes of soliciting the purchase or sale of equity share of the Company. All the descriptions and projections are based on the Company's own analysis at the time of compilation, and their accuracy is not guaranteed. These data may be revised without prior announcement. The Company will neither assume nor compensate any loss of anybody resulting from decisions based on information provided here.

Our Business Segments

Electronics

Developing, manufacturing, purchasing and selling chemicals that used in printed circuit boards (PCB) and other electronic components



Medical and Pharmaceuticals

Manufacturing and marketing ethical pharmaceuticals, contract development and manufacturing organization (CDMO), manufacturing and selling dental prosthetics



ICT and Sustainability

Businesses included ICT, fine chemicals, energy, and food, etc.



FY2027/3 1Q Overview

Electronics

- Net sales increased by 26% year on year
 <Reasons> Continued yen depreciation and higher sales volume of PKG and rigid products.
 Foreign exchange Effects: + The depreciation of the yen had a positive impact on business results.
 Average exchange rate during the first quarter:
 <FY2026/3> 145.2 JPY/USD <FY2027/3> 160.5 JPY/USD
- PKG products: + Continued demand growth driven by AI adoption, sales volume increased, mainly for dry film products for memory applications.
- Rigid products: + Sales volume increased, mainly for automotive and high-density interconnect (HDI) applications.
- Sales volume of display (white dry film) products decreased.
- Price revision: + In response to rising raw material and other expenses, prices of certain products were revised for shipments from June onward.
- Received the JPCA Encouragement Prize at the 22nd JPCA Award
 "Hole-Plugging Ink for Next-Generation High-Speed Communication PCBs"

Medical and Pharmaceuticals

- Net sales decreased by 2% year on year
 <Reasons> Lower sales volume due to declining demand in the Manufacturing and Marketing business.
- Manufacturing and marketing business: - Sale volume decreased due to lower demand for cough suppressants and expectorants, as well as the resolution of supply shortages of drugs with the same indications at other companies.
- Sales volume decreased for items subject to the elective care scheme.
- Contract manufacturing business: + Contract volume from exiting customers increased.
+ The product mix has been improved.

Company

- Revised upward the forecast for the fiscal year ended March 31, 2027 (FY 2027)
 Revised to reflect higher-than-expected performance of the Electronics business and the special employee benefit expenses recorded in the first quarter.
- Sponsored an esports competition "Street Fighter League JAPAN 2026"

Consolidated Financial Results Summary

	①	②	②-①	(②-①)/①	③	②/③	④	②/④
Unit : JPY Million	2026/3 1Q Result	2027/3 1Q Result	YoY	% of Changes	2027/3 1 st -Half Forecast (Announced on April 30)	% of Progress	2027/3 Full-Year Forecast (Announced on April 30)	% of Progress
Net Sales	33,179	39,019	5,840	18%	73,100	53%	146,300	27%
Operating Income	7,055	10,505	3,450	49%	16,800	63%	34,300	31%
Ordinary Income	6,657	11,220	4,563	69%	16,300	69%	33,400	34%
Net Income	4,636	7,500	2,863	62%	11,800	64%	24,100	31%
Exchange rate of JPY/USD	145.2	160.5	15.3		150.0		150.0	
EBITDA	9,176	12,680	3,503	38%	21,100	60%	43,200	29%
Operating Income Margin	21%	27%			23%		23%	
EBITDA Margin	28%	32%			29%		30%	

Performance by Segment


Cumulative Net Sales, Operating Income and EBITDA

		①	②	②-①	(②-①)/①	③	②/③	④	②/④
Unit : JPY Million		2026/3 1Q Result	2027/3 1Q Result	YoY	% of Changes	2027/3 1 st -Half Forecast (Announced on April 30)	% of Progress	2027/3 Full-Year Forecast (Announced on April 30)	% of Progress
Electronics	Net Sales	22,232	28,049	5,817	26%	51,600	54%	102,200	27%
	Operating Income	6,201	9,761	3,560	57%	15,500	63%	31,300	31%
	Operating Income Margin	28%	35%			30%		31%	
	EBITDA	7,096	10,725	3,628	51%	17,400	62%	35,200	30%
	EBITDA Margin	32%	38%			34%		34%	
Medical and Pharmaceuticals	Net Sales	9,419	9,203	(216)	(2%)	18,300	50%	37,500	25%
	Operating Income	1,378	772	(606)	(44%)	1,800	43%	4,000	19%
	Operating Income margin	15%	8%			10%		11%	
	EBITDA	2,356	1,739	(616)	(26%)	3,800	46%	8,000	22%
	EBITDA Margin	25%	19%			21%		21%	
ICT and Sustainability	Net Sales	1,527	1,766	239	16%	-	-	-	-
	Operating Income	(32)	135	167	-	-	-	-	-
	Operating Income Margin	(2%)	8%			-	-	-	-
Company Expense	Operating Income / Loss	(492)	(164)	328		-	-	-	-

Trend of Quarterly Performance

Net Sales and Operating Income

Unit : JPY Million



BS- Comparison with the Previous Term

Unit : JPY Million

	2026/3	2026/6	Changes		2026/3	2026/6	Changes
Cash and Deposits	43,203	45,700	2,497	Notes and Account Payable	9,501	11,551	2,049
Accounts Receivables* ¹	34,317	37,510	3,192	Short Term Borrowings* ³	15,754	18,088	2,334
Inventories* ²	21,653	23,281	1,627	Long Term Borrowings	41,098	35,576	(5,521)
Others	3,939	2,565	(1,373)	Others	19,816	20,294	478
Total Current Assets	103,115	109,058	5,943	Total Liabilities	86,170	85,510	(659)
Tangible Fixed Assets	70,501	71,219	718	Shareholders Equity	100,983	108,482	7,499
Intangible Fixed Assets	14,465	14,004	(460)	Accumulated Other Comprehensive Income	14,761	17,828	3,066
Investments and Other Assets	13,846	17,561	3,714	Non-Controlling Interest	12	20	8
Total Fixed Assets	98,813	102,785	3,972	Total Net Assets	115,757	126,332	10,574
Total Assets	201,928	211,843	9,915	Total Liabilities and Net Assets	201,928	211,843	9,915
				Equity to Asset Ratio	57.3%	59.6%	2.3%

*1 Accounts Receivables : Notes Receivable + Accounts Receivable-Trade + Contract Asset

*2 Inventories : Merchandise and Finished Goods + Work in Process + Raw Materials and Supplies

*3 Short-Term Borrowings : Short-Term Borrowings + Long-Term Borrowings Scheduled to Be Repaid within One Year

Revised Forecast for the 1st-Half of Fiscal Year Ended March 31, 2027 (FY 2027)

- ✓ We have revised the 1st-half forecast for FY 2027. The reasons for revision are as follows.
- The results of the Electronics business in the 1st quarter outperformed our forecast.
 - Special employee benefit expenses have been recorded as an extraordinary loss in the 1st quarter.

Unit : JPY Million		2027/3 1st-half Forecast (Announced on April 30) ^{*1}		2027/3 1st-half Forecast (Announced on July 31) ^{*2}		Change Ratio	
		Amount	Profit ratio	Amount	Profit ratio	Amount	Ratio
Consolidated	Net Sales	73,100		75,900		+2,800	+4%
	Operating Income	16,800	23%	18,900	25%	+2,100	+13%
	Ordinary Income	16,300	22%	19,200	25%	+2,900	+18%
	Net Income	11,800	16%	13,100	17%	+1,300	+11%
	EBITDA	21,100	29%	23,200	31%	+2,100	+10%
Electronics	Net Sales	51,600		54,400		+2,800	+5%
	Operating Income	15,500	30%	17,600	32%	+2,100	+14%
	EBITDA	17,400	34%	19,500	36%	+2,100	+12%
Medical and Pharmaceuticals	Net Sales	18,300		18,300		-	-
	Operating Income	1,800	10%	1,800	10%	-	-
	EBITDA	3,800	21%	3,800	21%	-	-

*1 150.0 JPY/USD

*2 The 1st-half forecast has been revised by remaining the 2nd-quarter forecast announced on April 30, 2026 unchanged, replacing the 1st-quarter forecast for the Electronics business with the actual results and taking into account the extraordinary loss recorded in the 1st quarter.

1Q actual results: 160.5 JPY/USD, 2Q forecast (announced at the beginning of FY 2027) : 150.0 JPY/USD

Revised Forecast for the Fiscal Year Ended March 31, 2027 (FY 2027)

- ✓ We have revised the full-year forecast for FY 2027. The reasons for revision are as follows.
- The results of the Electronics business in the 1st quarter outperformed our forecast.
 - Special employee benefit expenses have been recorded as an extraordinary loss in the 1st quarter.

Unit : JPY Million		2027/3 Full-Year Forecast (Announced on April 30) ^{*1}		2027/3 Full-Year Forecast (Announced on July 31) ^{*2}		Change Ratio	
		Amount	Profit ratio	Amount	Profit ratio	Amount	Ratio
Consolidated	Net Sales	146,300		149,100		+2,800	+2%
	Operating Income	34,300	23%	36,400	24%	+2,100	+6%
	Ordinary Income	33,400	23%	36,300	24%	+2,900	+9%
	Net Income	24,100	16%	25,400	17%	+1,300	+5%
	EBITDA	43,200	30%	45,300	30%	+2,100	+5%
Electronics	Net Sales	102,200		105,000		+2,800	+3%
	Operating Income	31,300	31%	33,400	32%	+2,100	+7%
	EBITDA	35,200	34%	37,300	36%	+2,100	+6%
Medical and Pharmaceuticals	Net Sales	37,500		37,500		-	-
	Operating Income	4,000	11%	4,000	11%	-	-
	EBITDA	8,000	21%	8,000	21%	-	-

*1 150.0 JPY/USD

*2 The full-year forecast has been revised by remaining the 2nd-quarter onward forecast announced on April 30, 2026 unchanged, replacing the 1st-quarter forecast for the Electronics business with the actual results and taking into account the extraordinary loss recorded in the 1st quarter.

1Q actual results: 160.5 JPY/USD, 2Q to 4Q forecast (announced at the beginning of FY 2027) : 150.0 JPY/USD



Electronics

Electronics Terminology


Term	Definition
PCB	<u>P</u> rinted <u>C</u> ircuit <u>B</u> oard
SR	<u>S</u> older <u>R</u> esist, also known as Solder Mask
PKG	Semiconductor <u>P</u> ack <u>a</u> ge
DF	<u>D</u> ry <u>F</u> ilm
BU	<u>B</u> uild- <u>u</u> p

Electronics Product Classification

Group	Category		Type	Remarks
PCB insulating materials	Rigid	Regular	Liquid	▪ SR materials for insulation and surface protection use ▪ Marking, etching and plating materials ▪ Electronic materials, etc.
		High end	Liquid／DF	
	PKG		Liquid／DF	
	FPC (Flexible printed circuit board)		Liquid／DF	
	BU		Liquid／DF	▪ Build-up materials for interlayer insulation and hole plugging use, etc.
Other related products	Others		Liquid／DF	▪ Conductive paste, etc.


Electronics Net Sales by Product Category

Unit : JPY Million



Electronics Net Sales by Sales Area

Unit : JPY Million



Won the 22nd JPCA Award


- ✓ Taiyo Ink Mfg. received the JPCA Encouragement Prize at the 22nd JPCA Award hosted by the Japan Electronics Packaging and Circuits Association. This marks the seventh consecutive year in which Taiyo Ink Mfg. has won the JPCA Award.

Technological trends in high-speed communication PCBs

- Demand is growing for low-dielectric insulating materials for PCBs used in servers and communication equipment to support high-speed data transmission
- The back-drilling method*¹ is increasingly being adopted for multilayer PCBs used in servers and other applications to reduce transmission loss

Market expansion of high-layer-count PCBs for servers*²

- Within the high-speed communication PCB market, the market for high-layer-count PCBs for servers is growing, driven by demand for AI servers.




*¹ The back-drilling method is a technique used in high-speed multilayer PCBs to remove unnecessary portions of vias by drilling, thereby significantly reducing transmission loss and signal reflections

*² Source: Fuji Chimera Research Institute, 2025 Deta senta AI ki debaisu shijo chosa [2025 comprehensive survey of data center, AI, and key device markets]
(High-layer-count PCBs for servers include HDI)

Our Award-winning Product



Hole-Plugging Ink for Next-Generation High-Speed Communication PCBs



(Cross-sectional view of a multilayer PCB)

- In addition to the low-dielectric properties required for high-speed data transmission, it delivers superior quality and reliability when the back-drilling method is used
- In comparative tests with conventional products, void (small cavity) formation inside through holes was significantly suppressed




Medical and Pharmaceuticals

Medical and Pharmaceutical Terminology

Term	Definition
LLP	<u>L</u> ong <u>L</u> isted <u>P</u> roduct A drug for which the patent or re-examination period has expired, enabling the sale of generic drugs
CDMO	<u>C</u> ontract <u>D</u> evelopment <u>M</u> anufacturing <u>O</u> rganization Organizations contracted to manufacture and develop pharmaceutical formulations
GMP	<u>G</u> ood <u>M</u> anufacturing <u>P</u> ractice Standards for manufacturing control and quality of pharmaceuticals and quasi-drugs

Medical and Pharmaceuticals Net Sales by Company

Unit : JPY Million



	1Q YoY	QoQ
mystarz (Dental Prosthetics)	+54 [+13%]	+27 [+6%]
Taiyo Pharma Tech (CDMO)	+52 [+1%]	+375 [+7%]
Taiyo Pharma (Manufacturing and Marketing)	(322) [(10%)]	+371 [+15%]



Company

Sponsored an Esports Competition "Street Fighter League JAPAN 2026"

- ✓ We are continuing our sponsorship of "Street Fighter League JAPAN 2026," an esports competition organized by CAPCOM CO., LTD., as its top partner from the previous season. This season will mark our sixth year of our partnership.



Tournament

"Street Fighter League JAPAN 2026"

Date of the Event

Regular season	August 25 - December 11, 2026
Playoffs	January 10-11, 2027
Grand Final	February 23, 2027

©CAPCOM

- "Street Fighter League JAPAN 2026" official website (Japanese only) : <https://sf.esports.capcom.com/sfl>
- Our press release (Japanese only) : https://www.taiyo-hd.co.jp/lp/brand/assets/pdf/20260625_01.pdf

